期刊文献+

不同照射技术靶区及相关正常组织受量差异与剂量分布的比较 被引量:5

Comparison of dosimetry of target volume and normal tissue between IMRT and 3DCRT for postoperative patients with gastric cancer
下载PDF
导出
摘要 目的比较胃癌术后患者调强放射治疗(intensity modulated radiation therapy,IMRT)与三维适形放射治疗(three dimensional conformal radiotherapy,3DCRT)两种放疗技术靶区及相关正常组织受量差异与剂量分布。方法 15例具有胃癌术后放疗适应证患者分别制定IMRT和3DCRT两种放疗计划,均采用6MV-X线。3DCRT采用分野技术,尽量减少肝脏及肾脏受量;IMRT根据处方剂量要求选择优化参数。靶区设定的处方剂量是至少95%计划靶体积(planning target volume,PTV)接受45.00 Gy,至少99%PTV接受42.75 Gy。利用剂量体积直方图比较不同照射技术靶区和相关正常组织受量差异与剂量分布。结果①靶区剂量学比较:IMRT的适形度及剂量均匀性均优于3DCRT(P<0.05),但两种放疗技术PTV剂量差异无统计学意义(P>0.05)。②正常组织受量比较:IMRT技术中左肾V15,正常肝V30,脊髓最大剂量,均优于3DCRT(P<0.05);而右肾的剂量分布,两种放疗技术差异无统计学意义(P>0.05)。结论胃癌术后IMRT,其靶区剂量的适形度、剂量均匀性优于3DCRT,并能够较好地保护周围正常组织。 Objective To compare the dosimetry of target volume and normal tissue between intensity-modulater radiotherapy (IMRT) and 3 dimensional conformal radiotherapy (3 DCRT) in postoperative patients with gastric cancer. Methods Plans of IMRT and 3DCRT were designed for 15 gastric cancer patients with indications for postoperative radiotherapy, respectively. In order to minimize the amount of liver and kidney, dose prescriptions were 45.00 Gy for 95 % planning target volume (PTV) and 42. 75 Gy for 99 % PTV. Dose volume histogram and dose distributions of the two regimes were compared. Results ① No significant difference in the PVT was found between IMRT and 3 DCRT. However, IMRT plan showed better dose uniformity and conformity (P 〈 0.05 ). ② The V15 of left kidney, the V30 of liver and the maximum dose of spinal cord of IMRT were better than those of 3DCRT(P 〈 0. 05 ). However, no significant difference in the V15 of right kidney was discovered between the two methods. Conclusions The uniformity and conformity of IMRT are better than that of 3DCRT,and IMRT was better than 3DCRT in protecting the surrounding normal tissue.
作者 蔡明伟 杜驰
出处 《实用医院临床杂志》 2013年第5期112-114,共3页 Practical Journal of Clinical Medicine
关键词 胃癌 放射疗法 放疗技术 剂量学 Gastric cancer Radiotherapy Radiotherapy technology Dosimetry
  • 相关文献

参考文献10

  • 1Kutcher GJ,Burman C,Brewster L,et al.Histogram reduction method for cal cu I ating complication probabilities for thfee-dimensional treatment planning eval uat ions [J].Int J Radiat Oncol Biol Phys,1991,21(1):137.
  • 2李岩.胃癌肿瘤标志物及临床意义[J].实用医院临床杂志,2011,8(1):11-15. 被引量:53
  • 3王晋,张羽,冯岗,廖东彪,周筱秋,任素蓉,王东,杜小波.RKIP在胃癌中表达的意义[J].实用医院临床杂志,2010,7(4):118-119. 被引量:2
  • 4殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].第4版.北京:中国协和医科大学出版社,2007:399-426.
  • 5Macdonald JS,Smalley SR,Benedetti J,et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma ofthe stomach or gastroesophageal junction[J].N Engl J Med 2001,345:725-730.
  • 6Gunderson LL,Sosin H.Adenocarcinoma of the stomach:areas of failure in a reoperation series(second or symptomatic look)clinicopathologic correlation and implications for adjuvant therapy[J].Int J Hadiat Oncol Biol Phys,1982,8:1-11.
  • 7Landry J,Tepper JE,Wood WC,et al.Patterns of failure following curative resection of gastric carcinoma [J]. Int J Radiat Oncol Biol Phys,1990,19:1357-1362.
  • 8Ringash J,Perkins G,Lockwood G,et al.IMRT for adjuvant radiation in gastric cancer:a preferred plan [J].Int J Radiat Oncol Biol Phys,2003,57(2 Suppl):S381-382.
  • 9许奕,姚升宇,陈旭明,张铁宁,陈颖,颜歌,李洪凌,徐冰,赵国旗.胃癌术后调强和三维适形计划的剂量学比较[J].中国医学物理学杂志,2012,29(2):3225-3227. 被引量:7
  • 10胡伟刚,章真,徐志勇,顾卫列,陆惠忠,何少琴.三维适形与调强放疗技术在胃癌术后放疗中的剂量学比较[J].中华放射肿瘤学杂志,2007,16(4):273-276. 被引量:35

二级参考文献59

  • 1胡伟刚,章真,徐志勇,顾卫列,陆惠忠,何少琴.三维适形与调强放疗技术在胃癌术后放疗中的剂量学比较[J].中华放射肿瘤学杂志,2007,16(4):273-276. 被引量:35
  • 2Hsu PI,Chen CH, Hsieh CS. Alphal-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer [J]. Clin Cancer Res,2007,13 ( 3 ) :876-883.
  • 3Watanabe Y, Kim HS, Castoro RJ. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes [J]. Gastroenterology, 2009,136(7) :2149-2158.
  • 4Jung M,Jeung HC ,Lee SS. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. Journal of cancer research and clinical oncology[J]. 2010,136(4) :517-526.
  • 5Miyagawa K,Sakakura C ,Nakashima S. Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis [ J ]. Anticancer research ,2008,28(2B) : 1169-1179.
  • 6Economopoulos KP, Sergentanis TN. Need for clarification of data in the recent meta-analysis about p53 polymorphism and gastric cancer risk. International journal of cancer [J]. Journal international du cancer,2010,126 ( 10 ) :2509.
  • 7Deveci MS,Deveci G. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma [ J ]. Gastric cancer,2007,10 (2) : 112-116.
  • 8Tsamandas AC, Kardamakis D, Tsiamalos P, et al. The potential role of Bcl-2 expression, apoptosis and cell proliferation ( Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome[J]. Anticancer research ,2009,29 (2) :703-709.
  • 9Liakakos T, Xeropotamos N, Ziogas D. EGFR as a Prognostic Marker for Gastric Cancer [ J ]. World journal of surgery, 2008,32 ( 6 ) : 1225-1226.
  • 10Luan F,Wang M, You W, The correlation of TGF-alpha, EGFR in precancerous lesions and carcinoma of stomach with PCNA expression [J]. Zhonghua bing li xue za zhi Chinese journal of pathology, 1997,26( 1 ) :31-34.

共引文献121

同被引文献55

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部